Emergent Biosolutions Inc. revenue by segment EBS

Annual Quarterly

Emergent Biosolutions Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Medical Countermeasures MCM Product at $456.7 million, 61% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	649	743	1,044	1,049	1,118	1,774	1,555	1,106	782	561	489
Product	—	—	—	—	—	—	990 +9.6% share 63.6%	904 +49.0% share 81.7%	606 +43.9% share 77.5%	422 share 75.2%	—
Medical Countermeasures MCM Product	428 -9.7% share 66.0%	457 -10.4% share 61.5%	510 +14.0% share 48.9%	447 -22.8% share 42.6%	580 -1.1% share 51.9%	586 share 33.0%	—	—	—	—	—
Commercial Product	177 -29.9% share 27.3%	226 -43.3% share 30.4%	399 -19.8% share 38.2%	497 +28.6% share 47.4%	387 -11.7% share 34.6%	438 share 24.7%	—	—	—	—	—
Services	—	—	104 +42.2% share 9.9%	73 -30.7% share 6.9%	105 -66.2% share 9.4%	310 +86.1% share 17.5%	167 +108.4% share 10.7%	80 -19.1% share 7.2%	99 +43.5% share 12.6%	69 share 12.3%	—
All Other Revenue	44 -29.6% share 6.7%	60 -55.4% share 8.1%	135 +28.7% share 12.9%	105 share 10.0%	—	—	—	—	—	—	—
Contracts And Grants	22 -41.4% share 3.5%	38 +25.7% share 5.1%	30 +14.1% share 2.9%	26 -36.5% share 2.5%	41 -69.2% share 3.7%	134 +16.6% share 7.6%	115 -6.0% share 7.4%	122 +59.1% share 11.1%	77 +9.2% share 9.8%	70 share 12.6%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: EBS (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Gaithersburg, MD
SEC filer status: Accelerated filer
SEC CIK: 1367644

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.